鞍石生物科创板IPO进入已问询阶段

Core Viewpoint - Ansh Biotechnology Co., Ltd. has transitioned its IPO status to "inquired" on the Sci-Tech Innovation Board, indicating progress in its public offering process [1] Group 1: Company Overview - Ansh Biotechnology is an innovative biopharmaceutical company that has entered the commercialization phase, focusing on diseases with significant unmet clinical needs, particularly in oncology [1] - The company aims to provide high-quality innovative anti-tumor drugs through efficient independent research and development, enhancing the quality of life for patients [1] Group 2: IPO Details - The IPO application for Ansh Biotechnology was accepted on September 26 [1] - The company plans to raise 2.45 billion yuan through the IPO, which will be allocated to new drug research and development projects as well as to supplement working capital [1]